QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
NASDAQ:NMRD

Nemaura Medical (NMRD) Stock Price, News & Analysis

$0.08
+0.00 (+0.13%)
(As of 10:26 AM ET)
Today's Range
$0.08
$0.08
50-Day Range
$0.08
$0.24
52-Week Range
$0.07
$1.25
Volume
492 shs
Average Volume
133,381 shs
Market Capitalization
$2.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25

Nemaura Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,484.8% Upside
$4.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$14,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars


NMRD stock logo

About Nemaura Medical Stock (NASDAQ:NMRD)

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NMRD Stock Price History

NMRD Stock News Headlines

Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Acutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2M
See More Headlines
Receive NMRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/01/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NMRD
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.25
High Stock Price Target
$6.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+5,477.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.62) per share

Miscellaneous

Free Float
16,877,000
Market Cap
$2.20 million
Optionable
Optionable
Beta
-0.04
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Dewan Fazlul Hoque Chowdhury Ph.D. (Age 51)
    Chairman, CEO, President and Principal Financial & Accounting Officer
    Comp: $338.58k
  • Dr. Arash Ghadar (Age 47)
    Chief Operating Officer
  • Mr. Jay L. Warner
    Head of U.S. Commercial Operations
  • Mr. Thomas Bendix Mortensen
    Head of E.U. Commercial Operations & Marketing
  • Ms. Samantha Sanders
    Global Head of Digital Programs














NMRD Stock Analysis - Frequently Asked Questions

Should I buy or sell Nemaura Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NMRD shares.
View NMRD analyst ratings
or view top-rated stocks.

What is Nemaura Medical's stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Nemaura Medical's shares. Their NMRD share price targets range from $2.50 to $6.00. On average, they anticipate the company's stock price to reach $4.25 in the next year. This suggests a possible upside of 5,484.8% from the stock's current price.
View analysts price targets for NMRD
or view top-rated stocks among Wall Street analysts.

How have NMRD shares performed in 2024?

Nemaura Medical's stock was trading at $0.2190 on January 1st, 2024. Since then, NMRD shares have decreased by 65.3% and is now trading at $0.0761.
View the best growth stocks for 2024 here
.

How were Nemaura Medical's earnings last quarter?

Nemaura Medical Inc. (NASDAQ:NMRD) issued its quarterly earnings data on Monday, February, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter.

Who are Nemaura Medical's major shareholders?

Nemaura Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Nemaura Medical?

Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMRD) was last updated on 3/1/2024 by MarketBeat.com Staff